How should hepatitis C virus be managed in a patient co-infected with HIV?

Management of HCV in HIV-Coinfected Patients

HIV/HCV-coinfected patients should be treated identically to HCV-monoinfected patients using interferon-free, direct-acting antiviral (DAA) regimens, with the critical caveat that drug-drug interactions with antiretroviral therapy must be carefully evaluated and managed. 1

Core Treatment Principles

Treatment Approach

The paradigm has fundamentally shifted: HIV/HCV coinfection is no longer considered a "special population" requiring different treatment strategies 2. Interferon-free DAA treatment is recommended as a priority for HIV/HCV-coinfected patients 1. The sustained virologic response (SVR) rates in coinfected patients now match those in HCV monoinfection, typically exceeding 95% 3.

Critical Management Steps

1. Do NOT interrupt antiretroviral therapy to allow HCV treatment 1. This is a firm contraindication that was problematic in the interferon era but is no longer necessary.

2. Mandatory drug-drug interaction assessment before initiating DAA therapy 1. Consultation with an HIV treatment expert is recommended if the antiretroviral regimen requires modification 1.

Recommended Treatment Regimens by Genotype

Genotype 1

First-line options:

• Sofosbuvir/Velpatasvir (400mg/100mg): Single tablet once daily for 12 weeks without ribavirin for both treatment-naïve and treatment-experienced patients with or without compensated cirrhosis 4. The ASTRAL-5 trial demonstrated 100% SVR in HIV-coinfected genotype 1 patients 4.

• Sofosbuvir (400mg) + Daclatasvir (60mg): Once daily for 12 weeks 4. Achieved 97-98% SVR in HIV/HCV-coinfected patients across genotypes 1-4 1.

  • Critical dose adjustment: Daclatasvir must be reduced to 30mg with ritonavir/cobicistat-boosted atazanavir or cobicistat-boosted elvitegravir, and increased to 90mg with efavirenz 4.

• Ledipasvir/Sofosbuvir (90mg/400mg): Fixed-dose combination once daily 5.

Treatment-experienced patients with genotype 1a: Add weight-based ribavirin (1000mg if <75kg, 1200mg if ≥75kg) when using sofosbuvir/daclatasvir for 12 weeks, or extend to 24 weeks without ribavirin 4.

Genotype 2

Preferred regimen:

• Sofosbuvir/Velpatasvir: 12 weeks without ribavirin for all patients with or without cirrhosis 4. ASTRAL-5 showed 100% SVR (11/11) in HIV-coinfected genotype 2 patients 4.

Alternative:

• Sofosbuvir + Daclatasvir: 12 weeks without ribavirin 4.

Historical data with sofosbuvir plus ribavirin showed 88% SVR in HIV-coinfected patients, but this is suboptimal compared to modern regimens 1.

Genotype 3

Preferred regimen:

• Sofosbuvir/Velpatasvir:
  • Treatment-naïve without cirrhosis: 12 weeks without ribavirin 4
  • Treatment-experienced without cirrhosis OR any patient with cirrhosis: 12 weeks WITH weight-based ribavirin 4
  • ASTRAL-5 demonstrated 92% SVR in HIV-coinfected genotype 3 patients 4

Alternative:

• Sofosbuvir + Daclatasvir:
  • Treatment-naïve without cirrhosis: 12 weeks without ribavirin 4
  • Treatment-experienced without cirrhosis: 12 weeks with ribavirin 4
  • Cirrhotic patients: 24 weeks with ribavirin 4

Important: Sofosbuvir plus ribavirin alone is suboptimal and should not be used 4. Ledipasvir is not recommended for genotype 3 due to insufficient potency 4.

Genotype 4

Preferred options:

• Sofosbuvir/Velpatasvir: 12 weeks without ribavirin (100% SVR in ASTRAL-5) 4
• Ledipasvir/Sofosbuvir: 12 weeks without ribavirin 4

HIV-coinfected patients achieved 84% SVR with sofosbuvir plus ribavirin for 24 weeks in historical studies 1.

Critical Drug-Drug Interaction Considerations

Key Antiretroviral Interactions

Tenofovir + Ledipasvir/Sofosbuvir: Ledipasvir increases tenofovir levels, potentially enhancing nephrotoxicity, especially when combined with ritonavir-boosted protease inhibitors 5. Monitor renal function closely.

Daclatasvir dose adjustments are mandatory with certain antiretrovirals 4:

• Reduce to 30mg with atazanavir/ritonavir, atazanavir/cobicistat, or elvitegravir/cobicistat
• Increase to 90mg with efavirenz

Paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD): The 100mg ritonavir in this regimen will boost HIV protease inhibitors; discontinue additional ritonavir during HCV treatment 5. Do NOT use with efavirenz or rilpivirine due to significant adverse events and drug level alterations 5.

Special Populations and Considerations

Patients with Cirrhosis

Compensated cirrhosis (Child-Pugh A) does not change the fundamental treatment approach, though some regimens require ribavirin addition or duration extension as noted above 4.

Renal Impairment

For CrCl >30 mL/min, no dose adjustment needed for sofosbuvir-based regimens 5. For severe renal impairment (CrCl <30 mL/min), paritaprevir/ritonavir/ombitasvir/dasabuvir can be used for genotype 1 5.

HBV/HCV/HIV Triple Coinfection

Treat HCV with standard regimens 1. Monitor for HBV reactivation during and after HCV treatment; may require HBV antiviral therapy if significant HBV replication occurs 1. Most drug-drug interactions between DAAs and HBV antivirals are minimal, except potential renal monitoring needed with ledipasvir plus tenofovir 1.

Common Pitfalls to Avoid

1. Never discontinue antiretroviral therapy for HCV treatment 1
2. Always check drug-drug interactions before prescribing—this is non-negotiable 1
3. Do not assume dose equivalence for daclatasvir across different antiretroviral regimens 4
4. Avoid sofosbuvir plus ribavirin alone for genotype 3—it is suboptimal 4
5. Screen all HIV patients for HCV (anti-HCV testing mandatory) 1
6. Confirm with HCV RNA in patients with unexplained liver disease, even if anti-HCV negative 1

Monitoring and Follow-up

Unlike interferon-based therapy, on-treatment viral load monitoring is no longer required given the high efficacy and low viral breakthrough rates of DAA regimens 2. However, reinfection risk remains elevated in HIV-coinfected patients due to ongoing risk behaviors, particularly in men who have sex with men and people who inject drugs 6, 7.